Respiratory Syncytial Vírus okozta megbetegedések és a palivizumab (Synagis) technológiaelemzése I.

[1] Adamovich K.: Respiratory syncytial vírusfertőzés gyakorisága veszélyeztetett csecsemőkben, Orvosi Hetilap 2001, 142 (11), 557-560.
[2] Anonymous: Comment in: Pediatrics. 2000 Oct;106(4):866; PMID: 11183179
[3] Az Egészségügyi Minisztérium szakmai irányelve az egészség-gazdaságtani elemzések készítéséhez, LII. ÉVFOLYAM 11. SZÁM, 1313-1520. OLDAL, 2002. május 23., Egészségügyi Közlöny
[4] Brunvand L, Lindemann R, and Grogaard J,: Who shall not receive palivizumab?, Pediatrics, 2000, 106, 4, 866
[5] Canadian Coordinating Office for Health Technology Assessment.: Palivizumab (Synagis). Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 2003. Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
[6] Connor EM, Carlin D, Top Jr FH, and Weisman LE,: Questions about palivizumab (Synagis), Pediatrics, 1999, 103, 2, S35-S36
[7] Józ´wiak-Hagymásy J,: Az RS vírus elleni védőoltás egészségügyi gazdaságtani és technológia-elemzése Magyarországon. Szakdolgozat, Budapesti Corvinus Egyetem, Budapest, 2003.
[8] Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in highrisk infants – A systematic review. Archives of Pediatrics & Adolescent Medicine. 156(10). 2002. 1034-1041.
[9] Lofland J H, Touch S M, O, apos, Connor J P, Chatterton M L, Moxey E D, Paddock L E, Nash D B, Desai S A.: Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost effectiveness analysis. Clinical Therapeutics. 2000. 22(11). 1357- 1369.
[10] Malley R, Vernacchio L, Devincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Jafri HS, Sanchez PJ, Macdonald K, Montana JB, Thompson CM, Ambrosino DM, Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions, Pediatric Infectious Disease Journal 2000, 19, 1, 1-7.
[11] Moler FW, Brown RW, Faix RG, and Gilsdorf JR,: Comments on palivizumab (Synagis), Pediatrics, 1999, 103, 2, 495-497
[12] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
[13] Paremore L, Elliott JM, Bell EF, 2004 Impact and costeffectiveness of respiratory syncytial virus, Clinical Evidence, 1122-1129, Oxford, 2004.
[14] Oertel M, Driver L.: Palivizumab. Oak Brook, Illinois: University Health System Consortium. 2000. University HealthSystem Consortium (UHC).
[15] Sachin Kamal-Bahl, MS; Jalpa Doshi, MS; James Campbell, MD,: Economic Analyses of Respiratory Syncytial Virus Immunoprophylaxis in High-Risk Infants. Arch Pediatr Adolesc Med. 2002; 156: 1034-1041) Systematic Review)
[16] Scholz H,: Palivizumab—ein monoklonaler Antikorper zur passiven Immunprophylaxe von Respiratory-syncytial- Virus (RSV)-Infektionen, Zeitschrift fur Geburtshilfe und Neonatologie, 2000 May-June, 204, 3, 120-122.
[17] Scholz H, Palivizumab – A monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections., Chirurgische Praxis, 2001, 59, 1, 139-143
[18] Simpson S, Burls A.: A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis(R)) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. Birmingham: West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham. 2001. 33. West Midlands Health Technology Assessment Collaboration (WMHTAC).
[19] Shireman T I, Braman K S.: Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid’s high-risk children. Archives of Pediatrics & Adolescent Medicine. 2002. 156(12). 1251- 1255.
[20] Schrand L M, Elliott J M, Ross M B, Bell E F, Mutnick A H.: A cost-benefit analysis of RSV prophylaxis in highrisk infants. Annals of Pharmacotherapy. 2001. 35(10). 1186-1193.
[21] Stevens T P, Sinkin R A, Hall C B, Maniscalco W M, McConnochie K M. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Archives of Pediatrics & Adolescent Medicine. 2000. 154(1). 55-61.
[22] Subramanian KN, Weisman LE, Rhodes T, Ariag no R,Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D, Connor E,: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group., Pediatric Infectious Disease Journal, 1998 Febr. 17, 2, 110-115.
[23] Subramanian KNS, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FHJr, Carlin D, Connor E,: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group., Pediatric Infectious Disease Journal, 1998 17, 2, 110-115.
[24] Sze LL, Etches P, Robinson J L.: Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta. Paediatrics & Child Health. 6(8). 2002. 525-532.
[25] Vogel AM, Lennon DR, Broadbent R, Byrnes CA, Grimwood K, Mildenhall L, Richardson V, Rowley S,: Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants, J Paediatr.Child Health, 2002, 38, 6, 550-554
[26] Vogel A M, McKinlay M J, Ashton T, Lennon D R, Harding J E, Pinnock R, Graham D, Grimwood K, Pattemore P K, Schousboe M.: Cost-effectiveness of palivizumab in New Zealand. Journal of Paediatrics & Child Health. 38(4).2002